Study Condition(s): Soft Tissue Sarcoma

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Study Alias: JGDR

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT03283696 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to evaluate the safety of ifosfamide when added to olaratumab and doxorubicin in participants with soft tissue sarcoma (STS) that is advanced or has spread to another part(s) of the body.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Your participation could last up to 16 weeks, depending on how you and your tumor respond
  • Participant must have been diagnosed with advanced soft tissue sarcoma

  • Participant must have adequate blood and organ function

  • Participant must have stopped other anti-cancer treatment and must have recovered from side effects of that treatment, except for hair loss

  • Female and male participant who is able to have children must agree to use birth control during the study and for 12 weeks after the last dose of study drug. Female participant must not be pregnant or breastfeeding

  • Participant must not be enrolled in another clinical trial

  • Participant must not have received anticancer treatment that targets the entire body (like chemotherapy) or radiotherapy of the chest or pelvis

  • Participant's cancer must not be actively spreading to the central nervous system or brain

  • Participant must not have active infections, including HIV or hepatitis

  • Participant must not have a mental illness or social situation that would make it hard to meet the study requirements

  • Participant must not be planning/need major surgery during the study

Where to Participate

6 locations are currently available of 45 planned
Invalid Postal Code.
Please re-enter postal code.
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.